SLU-PP-332: The ERR Agonist at the Centre of Exercise Mimetic Research

SLU-PP-332 has become one of the most discussed compounds in metabolic and mitochondrial research communities — and for reasons that extend far beyond its name. It is frequently grouped with peptides due to its research context and lyophilized powder format, but SLU-PP-332 is technically a small molecule rather than a peptide. More importantly, it activates a receptor system — estrogen-related receptors (ERRs) — that sits at a remarkable intersection of energy metabolism, mitochondrial biology, and exercise physiology.

This guide focuses on what SLU-PP-332 is, how it works, why it's generating significant research interest, and how it fits into the broader landscape of metabolic and mitochondrial research compounds.

All content is for educational and research purposes only. SLU-PP-332 is designated for research use only and is not approved for human or veterinary use.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic pan-ERR agonist — a small molecule compound that activates all three members of the estrogen-related receptor family: ERRα, ERRβ, and ERRγ. The "pan" designation indicates broad activity across all three isoforms, rather than selective engagement of one.

It was developed at Saint Louis University (hence "SLU") and identified through screening programs looking for ERR activators relevant to metabolic disease. Unlike conventional peptides which consist of amino acid chains, SLU-PP-332 is a synthetic organic molecule — which accounts for its unusual solubility profile (it requires DMSO-based reconstitution rather than aqueous bacteriostatic water).

Proto Peptide supplies SLU-PP-332 5mg for controlled laboratory research. Note that reconstitution requires DMSO rather than bacteriostatic water — see our reconstitution guide for SLU-PP-332 for full handling instructions.

Estrogen-Related Receptors: The Biological Target

To understand SLU-PP-332's research profile, it's essential to understand what ERRs are and why they matter.

What Are ERRs?

Estrogen-related receptors (ERRα, ERRβ, ERRγ) are nuclear receptors — transcription factors that, when activated, bind directly to DNA and regulate gene expression. They are called "estrogen-related" because their DNA-binding domain resembles that of estrogen receptors (ERα and ERβ), but critically, ERRs do not bind estrogen and are not modulated by estrogen levels. They are "orphan" nuclear receptors — they were discovered before their physiological ligands were identified — and their activity is regulated primarily by co-activator proteins rather than small molecule ligands.

ERRs and Energy Metabolism

ERRs are among the most important transcriptional regulators of energy metabolism in mammalian cells. They regulate:

Oxidative Phosphorylation Genes: ERRα and ERRγ directly regulate the transcription of genes encoding components of the mitochondrial electron transport chain — including complexes I, II, III, IV, and V. When ERR activity is high, mitochondria are more numerous, more structurally complete, and more efficient at generating ATP via oxidative phosphorylation.

Fatty Acid Oxidation: ERRα regulates the transcription of genes involved in fatty acid oxidation (FAO) — the process by which cells burn fat for energy rather than storing it. Enhanced ERR activity promotes a metabolic phenotype characterised by preferential fat utilisation, increased mitochondrial beta-oxidation, and improved metabolic flexibility.

Mitochondrial Biogenesis: ERRα is a transcriptional target and co-activator of PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) — the master regulator of mitochondrial biogenesis. ERRα and PGC-1α form a positive feedback loop: PGC-1α activates ERRα transcription, and ERRα co-activates PGC-1α target genes. This circuit is central to the cellular response to exercise and energy demand.

Exercise Response: The gene expression profile that ERRs drive — increased mitochondrial density, enhanced oxidative phosphorylation capacity, improved fatty acid oxidation — is precisely the adaptive response that occurs in skeletal muscle after endurance exercise training. This is why ERR agonists like SLU-PP-332 are described as "exercise mimetics": they activate the same transcriptional programs that exercise activates, through the ERR-PGC-1α axis.

SLU-PP-332's Mechanisms of Action

When SLU-PP-332 binds to ERRα, ERRβ, and ERRγ as a pan-agonist, it stabilises the receptor in its active conformation, enhancing transcriptional activity without requiring a physiological ligand. The downstream effects documented in preclinical research include:

Mitochondrial Biogenesis

SLU-PP-332 administration in animal models has been associated with increased mitochondrial density in skeletal muscle — measured by increases in mitochondrial DNA copy number, upregulation of mitochondrial biogenesis genes, and structural changes in muscle fibre composition toward more oxidative (endurance-type) characteristics.

Enhanced Oxidative Metabolism

ERR activation by SLU-PP-332 increases the expression of ETC complex genes, improving the muscle cell's capacity for oxidative phosphorylation. In treated animal models, this translates to enhanced running endurance and improved exercise capacity — the core evidence for the "exercise mimetic" characterisation.

Fatty Acid Oxidation

ERRα's role in regulating fat oxidation genes means SLU-PP-332 promotes fat utilisation over glucose for energy production in metabolic tissues. This is of direct research interest for obesity, metabolic syndrome, and type 2 diabetes models where impaired fat oxidation and metabolic inflexibility are key features.

Cardiac and Skeletal Muscle Metabolism

ERRs are highly expressed in cardiac and skeletal muscle — tissues with exceptionally high energy demands. SLU-PP-332's metabolic effects in these tissues are particularly relevant for research into heart failure, sarcopenia, metabolic myopathy, and the metabolic consequences of physical inactivity.

Why SLU-PP-332 Is Significant in Research

The concept of an exercise mimetic — a compound that activates the same transcriptional programs as exercise without requiring physical activity — has long been a research goal for several reasons:

Metabolic Disease Models: Many metabolic disease models (type 2 diabetes, obesity, metabolic syndrome) involve mitochondrial dysfunction, impaired fatty acid oxidation, and reduced oxidative phosphorylation capacity — all of which SLU-PP-332 addresses through ERR activation.

Sarcopenia and Muscle Aging Research: Age-related muscle loss (sarcopenia) involves reduced mitochondrial biogenesis, decreased oxidative capacity, and metabolic inflexibility. SLU-PP-332 is a relevant tool for studying interventions in this model.

Cardiovascular Research: Cardiac ERR activity is essential for maintaining the heart's energy metabolism under physiological and pathological stress. SLU-PP-332 enables investigation of ERR-mediated cardiac metabolic protection.

Exercise Biology: For researchers studying the molecular mechanisms of how exercise benefits metabolic health, SLU-PP-332 provides a pharmacological tool to activate the exercise-responsive transcriptional program in a controlled, dose-dependent manner — separating the metabolic effects of exercise from its mechanical and neurological components.

SLU-PP-332 vs. Other Mitochondrial Research Compounds

SLU-PP-332 vs. MOTS-C

MOTS-C activates AMPK — the cellular energy sensor — producing exercise-mimetic metabolic effects through a kinase-based pathway. SLU-PP-332 activates ERRs — nuclear receptors regulating mitochondrial gene expression — producing exercise-mimetic effects through a transcriptional pathway. Both activate mitochondrial biogenesis ultimately, but through distinct upstream mechanisms, making them complementary rather than redundant tools.

SLU-PP-332 vs. NAD+

NAD+ supports sirtuin activity and electron transport function — improving mitochondrial efficiency within existing mitochondria. SLU-PP-332 drives the creation of new mitochondria (biogenesis) through ERR-PGC-1α activation. These are different levels of intervention: quantity of mitochondria (SLU-PP-332) vs. efficiency of existing mitochondria (NAD+).

SLU-PP-332 vs. SS-31

SS-31 (Elamipretide) is a mitochondria-targeted antioxidant that protects the inner mitochondrial membrane from oxidative damage. SLU-PP-332 drives mitochondrial biogenesis and metabolic gene expression. They address different aspects of mitochondrial biology — damage protection (SS-31) vs. capacity enhancement (SLU-PP-332).

Handling Notes: DMSO-Based Reconstitution

SLU-PP-332 is not water-soluble in aqueous systems alone. It requires DMSO (dimethyl sulfoxide) as an initial solvent:

  1. Dissolve SLU-PP-332 in a calculated volume of DMSO first (it is soluble in DMSO at ~75mg/mL)
  2. Once dissolved, aqueous buffer (PBS or BAC water) can be added slowly to dilute to working concentration
  3. Final DMSO percentage in aqueous assays should generally not exceed 0.1–1% depending on cell sensitivity

DMSO safety: Always handle DMSO with gloves and eye protection. DMSO penetrates skin and can carry dissolved compounds across the skin barrier.

See our detailed SLU-PP-332 reconstitution guide for complete step-by-step instructions.

Storage:

  • Lyophilized: -20°C, dark and dry environment
  • Avoid moisture (especially important for hydrophobic small molecules)
  • DMSO stock solutions: store at 4°C, use within 1–2 weeks

Sourcing SLU-PP-332 in Canada

Proto Peptide offers SLU-PP-332 5mg for research use in Canada and the USA at ≥99% HPLC-verified purity. View our FAQ page for documentation requests and our full catalog for our complete research compound range.

Frequently Asked Questions

Is SLU-PP-332 a peptide? No. SLU-PP-332 is a small synthetic organic molecule — an ERR agonist — not a peptide (which is a chain of amino acids). It is grouped with research peptides in commercial contexts because it is supplied in a similar format and used in similar research applications, but it is chemically distinct.

Why does SLU-PP-332 require DMSO for reconstitution? SLU-PP-332 is hydrophobic and does not dissolve in aqueous solvents (like bacteriostatic water) without an organic co-solvent. DMSO breaks down the hydrophobic interactions that prevent aqueous dissolution.

What's the difference between an ERR agonist and a PPAR agonist? ERRs and PPARs are both nuclear receptors involved in energy metabolism, but they regulate different gene sets and respond to different signals. PPARα is the primary receptor targeted by fibrates (drugs used to lower triglycerides) and regulates fatty acid catabolism in the liver. ERRs, particularly ERRα, co-ordinate the broader mitochondrial biogenesis and oxidative phosphorylation program. SLU-PP-332's ERR agonism produces a more mitochondria-centric effect profile than PPAR agonism.

What makes SLU-PP-332 a "pan-ERR" agonist? "Pan" means it activates all three ERR isoforms (α, β, and γ). Some ERR modulators are selective for one isoform; SLU-PP-332's broad activation across all three produces a comprehensive ERR-mediated transcriptional response.

Conclusion

SLU-PP-332 represents a distinct class of research compound — a small molecule nuclear receptor agonist that activates the ERR-PGC-1α transcriptional axis governing mitochondrial biogenesis and oxidative metabolism. Its capacity to pharmacologically reproduce the mitochondrial adaptation to endurance exercise makes it a uniquely valuable tool for metabolic, mitochondrial, and exercise biology research. For researchers studying energy expenditure, mitochondrial capacity, and the cellular response to metabolic stress, SLU-PP-332 addresses these questions at the level of gene regulation — a mechanistic level that complements the kinase-targeting and cofactor-level approaches of MOTS-C and NAD+.

Proto Peptide supplies SLU-PP-332 5mg for Canadian and US research use. Browse our complete catalog for our full research compound range.

This content is intended for informational and educational purposes only. All products are for research use only and are not approved for human or veterinary use. Statements have not been evaluated by the FDA or Health Canada. Always follow your institution's guidelines and consult safety data sheets before handling any research chemical.

Back to blog